Alpha Tau Publishes Long-Term Safety and Efficacy Data in Cancers Journal for Multiple Hard-to-Treat Superficial Cancers

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), a company specializing in alpha-radiation cancer therapy through its innovative Alpha DaRT™ technology, announced the publication of a significant study in the journal Cancers. The article, titled “Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers,” was co-authored by clinical researchers from Israel, Italy, and the United States.

The primary objective of this comprehensive analysis was to assess long-term toxicity outcomes and disease control rates in patients treated with Alpha DaRT. The analysis pooled data from four international clinical trials, encompassing a total of 81 patients with tough-to-treat tumors in the head, neck, oral cavity, and skin. With a median follow-up of 14 months, extending up to 51 months, the study revealed an overwhelming overall response rate of 99%, with a complete response observed in 89% of treated lesions. Notably, there were no late-stage toxicities of grade 2 or higher reported, and the two-year local recurrence-free survival rate stood at 77%.

The findings illustrated that Alpha DaRT might offer sustained tumor control, extending beyond the immediate aftermath of treatment, potentially resulting in long-lasting disease management. The absence of significant long-term toxicities is particularly promising, suggesting Alpha DaRT as a viable long-term treatment option for these challenging cancer types. Ongoing follow-up and additional clinical studies are anticipated to further delineate the safety and effectiveness of Alpha DaRT.

Uzi Sofer, CEO of Alpha Tau, expressed optimism regarding the long-term data and its publication in Cancers. He highlighted that the detailed pooled analysis supports the enduring benefits of Alpha DaRT for patients with limited treatment options for hard-to-treat cancers. Sofer emphasized that the ongoing studies in various tumor types underscore the potential of Alpha DaRT in the fight against the most challenging cancers.

Dr. Robert Den, Chief Medical Officer at Alpha Tau, also commented on the gratifying nature of the long-term analysis publication. He noted that the study, which spans up to 51 months, showcases strong durability and a favorable safety profile, potentially paving the way for new therapeutic options for patients with limited alternatives. Dr. Den also mentioned the excitement surrounding results from several ongoing and planned clinical trials in other areas such as pancreas, brain, vulva, lung, and liver metastases.

Prof. Aron Popovtzer, Head of the Sharett Institute of Oncology at Hadassah Medical Center in Jerusalem and lead author of the publication, remarked on the enhanced clinical picture provided by this analysis. He pointed out that the long-term safety and efficacy results compare favorably with other radiotherapeutic studies using external beam radiation, but with significantly fewer complications. Prof. Popovtzer expressed hope for the future application of Alpha DaRT in treating various solid tumors and in combination with systemic therapies like immunotherapy and chemotherapy.

Alpha DaRT™ (Diffusing Alpha-emitters Radiation Therapy) is designed to deliver potent and highly focused alpha-irradiation directly to solid tumors by intertumoral deposition of radium-224 impregnated sources. As the radium decays, it releases short-lived daughter atoms that emit high-energy alpha particles, aiming to destroy the tumor while sparing the surrounding healthy tissue.

Founded in 2016, Alpha Tau is an Israeli company dedicated to the research, development, and potential commercialization of Alpha DaRT for treating solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.